查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
狂犬病疫苗市场：按产品类型、按预防类型、按应用、按最终用户：2023-2032 年全球机会分析和产业预测
市场调查报告书
商品编码
1414740

狂犬病疫苗市场：按产品类型、按预防类型、按应用、按最终用户：2023-2032 年全球机会分析和产业预测

Rabies Vaccine Market By Product Type, By Prophylaxis Type, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 451 Pages | 商品交期: 2-3个工作天内

价格

2022年狂犬病疫苗市值为12亿美元，预计2023年至2032年复合年增长率为4.7%，2032年达到19亿美元。

狂犬病疫苗市场-IMG1

狂犬病是一种透过受感染动物的唾液传染给人类的病毒。狂犬病病毒通常透过咬伤传播。狂犬病是人类感染狂犬病病毒所引起的疾病。它会导致以下症状：

1 癫痫、幻觉、瘫痪。狂犬病疫苗是预防狂犬病的疫苗。狂犬病疫苗是预防狂犬病的疫苗。狂犬病疫苗用于在接触狗咬伤或蝙蝠咬伤引起的狂犬病病毒之前和之后的一段时间内预防狂犬病。

狂犬病疫苗市场的成长是由于狂犬病患病率的增加、政府措施的增加以及狂犬病疫苗意识的迅速提高而推动的。动物和人类狂犬病的发生率是狂犬病疫苗市场的关键驱动因素。狂犬病流行地区对狂犬病疫苗的需求量很大，以防止狂犬病的传播。例如，据世界卫生组织（WHO）称，2023年9月，狂犬病被报告为一种疫苗可预防的病毒性疾病，在150多个国家和地区发生。它每年导致数万人死亡，主要发生在亚洲和非洲，其中 40% 是 15 岁以下的儿童。狗是狂犬病死亡的主要原因，占人类狂犬病感染的 99%。狂犬病可以透过给狗接种疫苗和防止狗咬伤来预防。

目录

第一章简介

第 2 章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
      • 狂犬病患病率上升
      • 政府倡议增多
    • 抑制因素
      • 人们对狂犬病的认知不足
    • 机会
      • 市场公司更采用关键策略

第四章狂犬病疫苗市场：依产品类型

  • 概述
  • 鸡胚细胞狂犬病疫苗
  • Vero细胞狂犬病疫苗
  • 人类二倍体细胞疫苗
  • 其他的

第五章狂犬病疫苗市场：依预防类型

  • 概述
  • 暴露前预防
  • 暴露后预防

第六章狂犬病疫苗市场：依应用分类

  • 概述
  • 人类
  • 对于动物

第七章狂犬病疫苗市场：依最终用户分类

  • 概述
  • 医院
  • 动物医院
  • 其他的

第八章狂犬病疫苗市场：按地区

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 其他的
  • 拉丁美洲/中东/非洲
    • 巴西
    • 沙乌地阿拉伯
    • 南非
    • 其他的

第9章 竞争形势

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 2022年主要企业定位

第十章 公司简介

  • Bharat Biotech International Limited
  • Sanofi
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • Cadila Pharmaceuticals Ltd
  • Merck & Co., Inc.
  • Serum Institute of India Pvt. Ltd.
  • Zoetis Inc.
  • Elanco Animal Health Incorporated.
  • Virbac SA
Product Code: A02924

According to a new report published by Allied Market Research, titled, "Rabies Vaccine Market," The rabies vaccine market was valued at $1.2 billion in 2022, and is estimated to reach $1.9 billion by 2032, growing at a CAGR of 4.7% from 2023 to 2032.

Rabies Vaccine Market - IMG1

Rabies is a virus spread to people from the saliva of infected animals. The rabies virus is usually transmitted through a bite. It is an illness that a person gets from an infection with the RABV virus. It causes symptoms such as

1) seizures, hallucinations, and paralysis. The rabies vaccine is a vaccine used to prevent rabies. Moreover, there are several rabies vaccines available that are both safe and effective. They are used to prevent rabies before, and, for a period, after exposure to the rabies virus, which is commonly caused by a dog bite or a bat bite.

The rabies vaccine market growth is driven by increase in prevalence of rabies, rise in initiatives taken by government, and surge in awareness regarding rabies vaccine. The incidence of rabies in animals and humans is a significant driver for the rabies vaccine market. In regions where rabies is endemic, there is a higher demand for rabies vaccines to prevent the spread of the disease. For instance, according to World Health Organization, (WHO), in September 2023, it was reported that, rabies is a vaccine-preventable viral disease which occurs in more than 150 countries and territories. It causes tens of thousands of deaths every year, mainly in Asia and Africa, 40% of whom are children under 15 years of age. Dogs are the main source of human rabies deaths, contributing up to 99% of all rabies transmissions to humans. Rabies can be prevented through vaccination of dogs and prevention of dog bites.

In addition, government-led rabies control and prevention programs often involve mass vaccination campaigns for animals and sometimes even free or subsidized vaccinations for humans who have been exposed to the virus. Government funding and support boost the market for rabies vaccines. Moreover, increased awareness about the risks of rabies and the importance of vaccination drive demand for rabies vaccines. Public health campaigns and educational efforts contribute to this awareness.

On the other hand, rabies vaccination, particularly post-exposure prophylaxis (PEP), is expensive. The high cost of treatment acts as a restraint, especially in regions with limited healthcare resources or where people are not able to afford the vaccine.

The rabies vaccine market is segmented into product type, prophylaxis type, application, end user, and region. By product type, the market is classified into chick embryo cells rabies vaccine, vero cell rabies vaccine, human diploid cell vaccine and others. Others includes purified duck embryo vaccine and baby hamster kidney (BHK) cells rabies vaccine. By prophylaxis type, the market is categorized into pre-exposure prophylaxis and post exposure prophylaxis. By application, the market is segmented into human and animal. By end user, the market is divided into hospitals, veterinary clinics, and others. Others segment includes vaccine centers and specialty clinics.

Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Major key players that operate in the global rabies vaccine market are Bharat Biotech International Limited, Zoetis, Sanofi, Boehringer Ingelheim International GmbH, Serum Institute of India Pvt. Ltd., Novartis AG, Cadila Pharmaceuticals, Merck & Co., Inc. Elanco Animal Health Incorporated., and Virbac SA. Key players operating in the market have adopted product approval, product launch, acquisition, and agreement as their key strategies to expand their rabies vaccine market share.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the rabies vaccine market analysis from 2022 to 2032 to identify the prevailing rabies vaccine market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the rabies vaccine market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global rabies vaccine market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Product Benchmarking / Product specification and applications
  • Upcoming/New Entrant by Regions
  • New Product Development/ Product Matrix of Key Players
  • Patient/epidemiology data at country, region, global level
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Product Type

  • Chick embryo cells rabies vaccine
  • Vero cell rabies vaccine
  • Human diploid cell vaccine
  • Others

By Prophylaxis Type

  • Pre-exposure prophylaxis
  • Post-exposure prophylaxis

By Application

  • Human
  • Animal

By End User

  • Hospitals
  • Veterinary clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Serum Institute of India Pvt. Ltd.
    • Sanofi
    • Boehringer Ingelheim International GmbH
    • Elanco Animal Health Incorporated.
    • Virbac SA
    • Novartis AG
    • Cadila Pharmaceuticals Ltd
    • Bharat Biotech International Limited
    • Zoetis Inc.
    • Merck & Co., Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of rabies
      • 3.4.1.2. Increase in initiative taken by government
    • 3.4.2. Restraints
      • 3.4.2.1. Lack of awareness among people regarding rabies
    • 3.4.3. Opportunities
      • 3.4.3.1. Rise in number of adoptions of key strategies by market players

CHAPTER 4: RABIES VACCINE MARKET, BY PRODUCT TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Chick embryo cells rabies vaccine
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Vero cell rabies vaccine
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Human diploid cell vaccine
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Pre-exposure prophylaxis
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Post-exposure prophylaxis
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: RABIES VACCINE MARKET, BY APPLICATION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Human
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Animal
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country

CHAPTER 7: RABIES VACCINE MARKET, BY END USER

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Hospitals
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by region
    • 7.2.3. Market share analysis by country
  • 7.3. Veterinary clinics
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by region
    • 7.3.3. Market share analysis by country
  • 7.4. Others
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by region
    • 7.4.3. Market share analysis by country

CHAPTER 8: RABIES VACCINE MARKET, BY REGION

  • 8.1. Overview
    • 8.1.1. Market size and forecast By Region
  • 8.2. North America
    • 8.2.1. Key market trends, growth factors and opportunities
    • 8.2.2. Market size and forecast, by Product Type
    • 8.2.3. Market size and forecast, by Prophylaxis Type
    • 8.2.4. Market size and forecast, by Application
    • 8.2.5. Market size and forecast, by End User
    • 8.2.6. Market size and forecast, by country
      • 8.2.6.1. U.S.
      • 8.2.6.1.1. Market size and forecast, by Product Type
      • 8.2.6.1.2. Market size and forecast, by Prophylaxis Type
      • 8.2.6.1.3. Market size and forecast, by Application
      • 8.2.6.1.4. Market size and forecast, by End User
      • 8.2.6.2. Canada
      • 8.2.6.2.1. Market size and forecast, by Product Type
      • 8.2.6.2.2. Market size and forecast, by Prophylaxis Type
      • 8.2.6.2.3. Market size and forecast, by Application
      • 8.2.6.2.4. Market size and forecast, by End User
      • 8.2.6.3. Mexico
      • 8.2.6.3.1. Market size and forecast, by Product Type
      • 8.2.6.3.2. Market size and forecast, by Prophylaxis Type
      • 8.2.6.3.3. Market size and forecast, by Application
      • 8.2.6.3.4. Market size and forecast, by End User
  • 8.3. Europe
    • 8.3.1. Key market trends, growth factors and opportunities
    • 8.3.2. Market size and forecast, by Product Type
    • 8.3.3. Market size and forecast, by Prophylaxis Type
    • 8.3.4. Market size and forecast, by Application
    • 8.3.5. Market size and forecast, by End User
    • 8.3.6. Market size and forecast, by country
      • 8.3.6.1. Germany
      • 8.3.6.1.1. Market size and forecast, by Product Type
      • 8.3.6.1.2. Market size and forecast, by Prophylaxis Type
      • 8.3.6.1.3. Market size and forecast, by Application
      • 8.3.6.1.4. Market size and forecast, by End User
      • 8.3.6.2. France
      • 8.3.6.2.1. Market size and forecast, by Product Type
      • 8.3.6.2.2. Market size and forecast, by Prophylaxis Type
      • 8.3.6.2.3. Market size and forecast, by Application
      • 8.3.6.2.4. Market size and forecast, by End User
      • 8.3.6.3. UK
      • 8.3.6.3.1. Market size and forecast, by Product Type
      • 8.3.6.3.2. Market size and forecast, by Prophylaxis Type
      • 8.3.6.3.3. Market size and forecast, by Application
      • 8.3.6.3.4. Market size and forecast, by End User
      • 8.3.6.4. Italy
      • 8.3.6.4.1. Market size and forecast, by Product Type
      • 8.3.6.4.2. Market size and forecast, by Prophylaxis Type
      • 8.3.6.4.3. Market size and forecast, by Application
      • 8.3.6.4.4. Market size and forecast, by End User
      • 8.3.6.5. Spain
      • 8.3.6.5.1. Market size and forecast, by Product Type
      • 8.3.6.5.2. Market size and forecast, by Prophylaxis Type
      • 8.3.6.5.3. Market size and forecast, by Application
      • 8.3.6.5.4. Market size and forecast, by End User
      • 8.3.6.6. Rest of Europe
      • 8.3.6.6.1. Market size and forecast, by Product Type
      • 8.3.6.6.2. Market size and forecast, by Prophylaxis Type
      • 8.3.6.6.3. Market size and forecast, by Application
      • 8.3.6.6.4. Market size and forecast, by End User
  • 8.4. Asia-Pacific
    • 8.4.1. Key market trends, growth factors and opportunities
    • 8.4.2. Market size and forecast, by Product Type
    • 8.4.3. Market size and forecast, by Prophylaxis Type
    • 8.4.4. Market size and forecast, by Application
    • 8.4.5. Market size and forecast, by End User
    • 8.4.6. Market size and forecast, by country
      • 8.4.6.1. Japan
      • 8.4.6.1.1. Market size and forecast, by Product Type
      • 8.4.6.1.2. Market size and forecast, by Prophylaxis Type
      • 8.4.6.1.3. Market size and forecast, by Application
      • 8.4.6.1.4. Market size and forecast, by End User
      • 8.4.6.2. China
      • 8.4.6.2.1. Market size and forecast, by Product Type
      • 8.4.6.2.2. Market size and forecast, by Prophylaxis Type
      • 8.4.6.2.3. Market size and forecast, by Application
      • 8.4.6.2.4. Market size and forecast, by End User
      • 8.4.6.3. India
      • 8.4.6.3.1. Market size and forecast, by Product Type
      • 8.4.6.3.2. Market size and forecast, by Prophylaxis Type
      • 8.4.6.3.3. Market size and forecast, by Application
      • 8.4.6.3.4. Market size and forecast, by End User
      • 8.4.6.4. Australia
      • 8.4.6.4.1. Market size and forecast, by Product Type
      • 8.4.6.4.2. Market size and forecast, by Prophylaxis Type
      • 8.4.6.4.3. Market size and forecast, by Application
      • 8.4.6.4.4. Market size and forecast, by End User
      • 8.4.6.5. South Korea
      • 8.4.6.5.1. Market size and forecast, by Product Type
      • 8.4.6.5.2. Market size and forecast, by Prophylaxis Type
      • 8.4.6.5.3. Market size and forecast, by Application
      • 8.4.6.5.4. Market size and forecast, by End User
      • 8.4.6.6. Rest of Asia-Pacific
      • 8.4.6.6.1. Market size and forecast, by Product Type
      • 8.4.6.6.2. Market size and forecast, by Prophylaxis Type
      • 8.4.6.6.3. Market size and forecast, by Application
      • 8.4.6.6.4. Market size and forecast, by End User
  • 8.5. LAMEA
    • 8.5.1. Key market trends, growth factors and opportunities
    • 8.5.2. Market size and forecast, by Product Type
    • 8.5.3. Market size and forecast, by Prophylaxis Type
    • 8.5.4. Market size and forecast, by Application
    • 8.5.5. Market size and forecast, by End User
    • 8.5.6. Market size and forecast, by country
      • 8.5.6.1. Brazil
      • 8.5.6.1.1. Market size and forecast, by Product Type
      • 8.5.6.1.2. Market size and forecast, by Prophylaxis Type
      • 8.5.6.1.3. Market size and forecast, by Application
      • 8.5.6.1.4. Market size and forecast, by End User
      • 8.5.6.2. Saudi Arabia
      • 8.5.6.2.1. Market size and forecast, by Product Type
      • 8.5.6.2.2. Market size and forecast, by Prophylaxis Type
      • 8.5.6.2.3. Market size and forecast, by Application
      • 8.5.6.2.4. Market size and forecast, by End User
      • 8.5.6.3. South Africa
      • 8.5.6.3.1. Market size and forecast, by Product Type
      • 8.5.6.3.2. Market size and forecast, by Prophylaxis Type
      • 8.5.6.3.3. Market size and forecast, by Application
      • 8.5.6.3.4. Market size and forecast, by End User
      • 8.5.6.4. Rest of LAMEA
      • 8.5.6.4.1. Market size and forecast, by Product Type
      • 8.5.6.4.2. Market size and forecast, by Prophylaxis Type
      • 8.5.6.4.3. Market size and forecast, by Application
      • 8.5.6.4.4. Market size and forecast, by End User

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product mapping of top 10 player
  • 9.4. Competitive dashboard
  • 9.5. Competitive heatmap
  • 9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

  • 10.1. Bharat Biotech International Limited
    • 10.1.1. Company overview
    • 10.1.2. Key executives
    • 10.1.3. Company snapshot
    • 10.1.4. Operating business segments
    • 10.1.5. Product portfolio
  • 10.2. Sanofi
    • 10.2.1. Company overview
    • 10.2.2. Key executives
    • 10.2.3. Company snapshot
    • 10.2.4. Operating business segments
    • 10.2.5. Product portfolio
    • 10.2.6. Business performance
  • 10.3. Boehringer Ingelheim International GmbH
    • 10.3.1. Company overview
    • 10.3.2. Key executives
    • 10.3.3. Company snapshot
    • 10.3.4. Operating business segments
    • 10.3.5. Product portfolio
    • 10.3.6. Business performance
    • 10.3.7. Key strategic moves and developments
  • 10.4. Novartis AG
    • 10.4.1. Company overview
    • 10.4.2. Key executives
    • 10.4.3. Company snapshot
    • 10.4.4. Operating business segments
    • 10.4.5. Product portfolio
    • 10.4.6. Business performance
  • 10.5. Cadila Pharmaceuticals Ltd
    • 10.5.1. Company overview
    • 10.5.2. Key executives
    • 10.5.3. Company snapshot
    • 10.5.4. Operating business segments
    • 10.5.5. Product portfolio
    • 10.5.6. Key strategic moves and developments
  • 10.6. Merck & Co., Inc.
    • 10.6.1. Company overview
    • 10.6.2. Key executives
    • 10.6.3. Company snapshot
    • 10.6.4. Operating business segments
    • 10.6.5. Product portfolio
    • 10.6.6. Business performance
  • 10.7. Serum Institute of India Pvt. Ltd.
    • 10.7.1. Company overview
    • 10.7.2. Key executives
    • 10.7.3. Company snapshot
    • 10.7.4. Operating business segments
    • 10.7.5. Product portfolio
  • 10.8. Zoetis Inc.
    • 10.8.1. Company overview
    • 10.8.2. Key executives
    • 10.8.3. Company snapshot
    • 10.8.4. Operating business segments
    • 10.8.5. Product portfolio
    • 10.8.6. Business performance
  • 10.9. Elanco Animal Health Incorporated.
    • 10.9.1. Company overview
    • 10.9.2. Key executives
    • 10.9.3. Company snapshot
    • 10.9.4. Operating business segments
    • 10.9.5. Product portfolio
    • 10.9.6. Business performance
  • 10.10. Virbac SA
    • 10.10.1. Company overview
    • 10.10.2. Key executives
    • 10.10.3. Company snapshot
    • 10.10.4. Operating business segments
    • 10.10.5. Product portfolio
    • 10.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 02. RABIES VACCINE MARKET FOR CHICK EMBRYO CELLS RABIES VACCINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. RABIES VACCINE MARKET FOR VERO CELL RABIES VACCINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. RABIES VACCINE MARKET FOR HUMAN DIPLOID CELL VACCINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. RABIES VACCINE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. GLOBAL RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 07. RABIES VACCINE MARKET FOR PRE-EXPOSURE PROPHYLAXIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. RABIES VACCINE MARKET FOR POST-EXPOSURE PROPHYLAXIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 10. RABIES VACCINE MARKET FOR HUMAN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. RABIES VACCINE MARKET FOR ANIMAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 13. RABIES VACCINE MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. RABIES VACCINE MARKET FOR VETERINARY CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. RABIES VACCINE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. RABIES VACCINE MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA RABIES VACCINE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 22. U.S. RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 23. U.S. RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 24. U.S. RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 25. U.S. RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 26. CANADA RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 27. CANADA RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 28. CANADA RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 29. CANADA RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 30. MEXICO RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 31. MEXICO RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 32. MEXICO RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 33. MEXICO RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 35. EUROPE RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 36. EUROPE RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 38. EUROPE RABIES VACCINE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 39. GERMANY RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 40. GERMANY RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 41. GERMANY RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 42. GERMANY RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. FRANCE RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 44. FRANCE RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 45. FRANCE RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 46. FRANCE RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 47. UK RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 48. UK RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 49. UK RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 50. UK RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 51. ITALY RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 52. ITALY RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 53. ITALY RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 54. ITALY RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. SPAIN RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 56. SPAIN RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 57. SPAIN RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 58. SPAIN RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. REST OF EUROPE RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 60. REST OF EUROPE RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 61. REST OF EUROPE RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 62. REST OF EUROPE RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 63. ASIA-PACIFIC RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 64. ASIA-PACIFIC RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 65. ASIA-PACIFIC RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 66. ASIA-PACIFIC RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 67. ASIA-PACIFIC RABIES VACCINE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 68. JAPAN RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 69. JAPAN RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 70. JAPAN RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 71. JAPAN RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 72. CHINA RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 73. CHINA RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 74. CHINA RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 75. CHINA RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 76. INDIA RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 77. INDIA RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 78. INDIA RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 79. INDIA RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 80. AUSTRALIA RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 81. AUSTRALIA RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 82. AUSTRALIA RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 83. AUSTRALIA RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 84. SOUTH KOREA RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH KOREA RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 86. SOUTH KOREA RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 87. SOUTH KOREA RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 88. REST OF ASIA-PACIFIC RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 89. REST OF ASIA-PACIFIC RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 90. REST OF ASIA-PACIFIC RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 91. REST OF ASIA-PACIFIC RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 92. LAMEA RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 93. LAMEA RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 94. LAMEA RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 95. LAMEA RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 96. LAMEA RABIES VACCINE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 97. BRAZIL RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 98. BRAZIL RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 99. BRAZIL RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 100. BRAZIL RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 101. SAUDI ARABIA RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 102. SAUDI ARABIA RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 103. SAUDI ARABIA RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 104. SAUDI ARABIA RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 105. SOUTH AFRICA RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 106. SOUTH AFRICA RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 107. SOUTH AFRICA RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 108. SOUTH AFRICA RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 109. REST OF LAMEA RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 110. REST OF LAMEA RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022-2032 ($MILLION)
  • TABLE 111. REST OF LAMEA RABIES VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 112. REST OF LAMEA RABIES VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 113. BHARAT BIOTECH INTERNATIONAL LIMITED: KEY EXECUTIVES
  • TABLE 114. BHARAT BIOTECH INTERNATIONAL LIMITED: COMPANY SNAPSHOT
  • TABLE 115. BHARAT BIOTECH INTERNATIONAL LIMITED: PRODUCT SEGMENTS
  • TABLE 116. BHARAT BIOTECH INTERNATIONAL LIMITED: PRODUCT PORTFOLIO
  • TABLE 117. SANOFI: KEY EXECUTIVES
  • TABLE 118. SANOFI: COMPANY SNAPSHOT
  • TABLE 119. SANOFI: PRODUCT SEGMENTS
  • TABLE 120. SANOFI: PRODUCT PORTFOLIO
  • TABLE 121. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY EXECUTIVES
  • TABLE 122. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
  • TABLE 123. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT SEGMENTS
  • TABLE 124. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
  • TABLE 125. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY STRATERGIES
  • TABLE 126. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 127. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 128. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 129. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 130. CADILA PHARMACEUTICALS LTD: KEY EXECUTIVES
  • TABLE 131. CADILA PHARMACEUTICALS LTD: COMPANY SNAPSHOT
  • TABLE 132. CADILA PHARMACEUTICALS LTD: PRODUCT SEGMENTS
  • TABLE 133. CADILA PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
  • TABLE 134. CADILA PHARMACEUTICALS LTD: KEY STRATERGIES
  • TABLE 135. MERCK & CO., INC.: KEY EXECUTIVES
  • TABLE 136. MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 137. MERCK & CO., INC.: PRODUCT SEGMENTS
  • TABLE 138. MERCK & CO., INC.: PRODUCT PORTFOLIO
  • TABLE 139. SERUM INSTITUTE OF INDIA PVT. LTD.: KEY EXECUTIVES
  • TABLE 140. SERUM INSTITUTE OF INDIA PVT. LTD.: COMPANY SNAPSHOT
  • TABLE 141. SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT SEGMENTS
  • TABLE 142. SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT PORTFOLIO
  • TABLE 143. ZOETIS INC.: KEY EXECUTIVES
  • TABLE 144. ZOETIS INC.: COMPANY SNAPSHOT
  • TABLE 145. ZOETIS INC.: PRODUCT SEGMENTS
  • TABLE 146. ZOETIS INC.: PRODUCT PORTFOLIO
  • TABLE 147. ELANCO ANIMAL HEALTH INCORPORATED.: KEY EXECUTIVES
  • TABLE 148. ELANCO ANIMAL HEALTH INCORPORATED.: COMPANY SNAPSHOT
  • TABLE 149. ELANCO ANIMAL HEALTH INCORPORATED.: PRODUCT SEGMENTS
  • TABLE 150. ELANCO ANIMAL HEALTH INCORPORATED.: SERVICE SEGMENTS
  • TABLE 151. ELANCO ANIMAL HEALTH INCORPORATED.: PRODUCT PORTFOLIO
  • TABLE 152. VIRBAC SA: KEY EXECUTIVES
  • TABLE 153. VIRBAC SA: COMPANY SNAPSHOT
  • TABLE 154. VIRBAC SA: PRODUCT SEGMENTS
  • TABLE 155. VIRBAC SA: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. RABIES VACCINE MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF RABIES VACCINE MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN RABIES VACCINE MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN RABIES VACCINE MARKET (2023-2032)
  • FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. LOW THREAT OF NEW ENTRANTS
  • FIGURE 07. LOW THREAT OF SUBSTITUTES
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. LOW BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL RABIES VACCINE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. RABIES VACCINE MARKET, BY PRODUCT TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF RABIES VACCINE MARKET FOR CHICK EMBRYO CELLS RABIES VACCINE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF RABIES VACCINE MARKET FOR VERO CELL RABIES VACCINE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF RABIES VACCINE MARKET FOR HUMAN DIPLOID CELL VACCINE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF RABIES VACCINE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF RABIES VACCINE MARKET FOR PRE-EXPOSURE PROPHYLAXIS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF RABIES VACCINE MARKET FOR POST-EXPOSURE PROPHYLAXIS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. RABIES VACCINE MARKET, BY APPLICATION, 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF RABIES VACCINE MARKET FOR HUMAN, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF RABIES VACCINE MARKET FOR ANIMAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. RABIES VACCINE MARKET, BY END USER, 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF RABIES VACCINE MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF RABIES VACCINE MARKET FOR VETERINARY CLINICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF RABIES VACCINE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 26. RABIES VACCINE MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 27. U.S. RABIES VACCINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. CANADA RABIES VACCINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. MEXICO RABIES VACCINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. GERMANY RABIES VACCINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. FRANCE RABIES VACCINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. UK RABIES VACCINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. ITALY RABIES VACCINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. SPAIN RABIES VACCINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. REST OF EUROPE RABIES VACCINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. JAPAN RABIES VACCINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. CHINA RABIES VACCINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. INDIA RABIES VACCINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. AUSTRALIA RABIES VACCINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SOUTH KOREA RABIES VACCINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. REST OF ASIA-PACIFIC RABIES VACCINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. BRAZIL RABIES VACCINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. SAUDI ARABIA RABIES VACCINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. SOUTH AFRICA RABIES VACCINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. REST OF LAMEA RABIES VACCINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 47. COMPETITIVE DASHBOARD
  • FIGURE 48. COMPETITIVE HEATMAP: RABIES VACCINE MARKET
  • FIGURE 49. TOP PLAYER POSITIONING, 2022
  • FIGURE 50. SANOFI: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 51. SANOFI: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 52. SANOFI: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 53. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 56. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 60. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 62. ZOETIS INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 63. ELANCO ANIMAL HEALTH INCORPORATED.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 64. ELANCO ANIMAL HEALTH INCORPORATED.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 65. ELANCO ANIMAL HEALTH INCORPORATED.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 66. VIRBAC SA: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 67. VIRBAC SA: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 68. VIRBAC SA: REVENUE SHARE BY REGION, 2022 (%)